@article{Escobar-2021-Integrated,
title = "Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms",
author = "Escobar, Andres and
Chiu, Phyllis and
Qu, Jianxi and
Zhang, Yushan and
Xu, Chang‐Qing and
Escobar, Andres and
Chiu, Phyllis and
Qu, Jianxi and
Zhang, Yushan and
Xu, Chang‐Qing",
journal = "Micromachines, Volume 12, Issue 9",
volume = "12",
number = "9",
year = "2021",
publisher = "MDPI AG",
url = "https://gwf-uwaterloo.github.io/gwf-publications/G21-118001",
doi = "10.3390/mi12091079",
pages = "1079",
abstract = "The rapid detection and quantification of infectious pathogens is an essential component to the control of potentially lethal outbreaks among human populations worldwide. Several of these highly infectious pathogens, such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been cemented in human history as causing epidemics or pandemics due to their lethality and contagiousness. SARS-CoV-2 is an example of these highly infectious pathogens that have recently become one of the leading causes of globally reported deaths, creating one of the worst economic downturns and health crises in the last century. As a result, the necessity for highly accurate and increasingly rapid on-site diagnostic platforms for highly infectious pathogens, such as SARS-CoV-2, has grown dramatically over the last two years. Current conventional non-microfluidic diagnostic techniques have limitations in their effectiveness as on-site devices due to their large turnaround times, operational costs and the need for laboratory equipment. In this review, we first present criteria, both novel and previously determined, as a foundation for the development of effective and viable on-site microfluidic diagnostic platforms for several notable pathogens, including SARS-CoV-2. This list of criteria includes standards that were set out by the WHO, as well as our own {``}seven pillars{''} for effective microfluidic integration. We then evaluate the use of microfluidic integration to improve upon currently, and previously, existing platforms for the detection of infectious pathogens. Finally, we discuss a stage-wise means to translate our findings into a fundamental framework towards the development of more effective on-site SARS-CoV-2 microfluidic-integrated platforms that may facilitate future pandemic diagnostic and research endeavors. Through microfluidic integration, many limitations in currently existing infectious pathogen diagnostic platforms can be eliminated or improved upon.",
}
<?xml version="1.0" encoding="UTF-8"?>
<modsCollection xmlns="http://www.loc.gov/mods/v3">
<mods ID="Escobar-2021-Integrated">
<titleInfo>
<title>Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms</title>
</titleInfo>
<name type="personal">
<namePart type="given">Andres</namePart>
<namePart type="family">Escobar</namePart>
<role>
<roleTerm authority="marcrelator" type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Phyllis</namePart>
<namePart type="family">Chiu</namePart>
<role>
<roleTerm authority="marcrelator" type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Jianxi</namePart>
<namePart type="family">Qu</namePart>
<role>
<roleTerm authority="marcrelator" type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Yushan</namePart>
<namePart type="family">Zhang</namePart>
<role>
<roleTerm authority="marcrelator" type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Chang‐Qing</namePart>
<namePart type="family">Xu</namePart>
<role>
<roleTerm authority="marcrelator" type="text">author</roleTerm>
</role>
</name>
<originInfo>
<dateIssued>2021</dateIssued>
</originInfo>
<typeOfResource>text</typeOfResource>
<genre authority="bibutilsgt">journal article</genre>
<relatedItem type="host">
<titleInfo>
<title>Micromachines, Volume 12, Issue 9</title>
</titleInfo>
<originInfo>
<issuance>continuing</issuance>
<publisher>MDPI AG</publisher>
</originInfo>
<genre authority="marcgt">periodical</genre>
<genre authority="bibutilsgt">academic journal</genre>
</relatedItem>
<abstract>The rapid detection and quantification of infectious pathogens is an essential component to the control of potentially lethal outbreaks among human populations worldwide. Several of these highly infectious pathogens, such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been cemented in human history as causing epidemics or pandemics due to their lethality and contagiousness. SARS-CoV-2 is an example of these highly infectious pathogens that have recently become one of the leading causes of globally reported deaths, creating one of the worst economic downturns and health crises in the last century. As a result, the necessity for highly accurate and increasingly rapid on-site diagnostic platforms for highly infectious pathogens, such as SARS-CoV-2, has grown dramatically over the last two years. Current conventional non-microfluidic diagnostic techniques have limitations in their effectiveness as on-site devices due to their large turnaround times, operational costs and the need for laboratory equipment. In this review, we first present criteria, both novel and previously determined, as a foundation for the development of effective and viable on-site microfluidic diagnostic platforms for several notable pathogens, including SARS-CoV-2. This list of criteria includes standards that were set out by the WHO, as well as our own “seven pillars” for effective microfluidic integration. We then evaluate the use of microfluidic integration to improve upon currently, and previously, existing platforms for the detection of infectious pathogens. Finally, we discuss a stage-wise means to translate our findings into a fundamental framework towards the development of more effective on-site SARS-CoV-2 microfluidic-integrated platforms that may facilitate future pandemic diagnostic and research endeavors. Through microfluidic integration, many limitations in currently existing infectious pathogen diagnostic platforms can be eliminated or improved upon.</abstract>
<identifier type="citekey">Escobar-2021-Integrated</identifier>
<identifier type="doi">10.3390/mi12091079</identifier>
<location>
<url>https://gwf-uwaterloo.github.io/gwf-publications/G21-118001</url>
</location>
<part>
<date>2021</date>
<detail type="volume"><number>12</number></detail>
<detail type="issue"><number>9</number></detail>
<detail type="page"><number>1079</number></detail>
</part>
</mods>
</modsCollection>
%0 Journal Article
%T Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms
%A Escobar, Andres
%A Chiu, Phyllis
%A Qu, Jianxi
%A Zhang, Yushan
%A Xu, Chang‐Qing
%J Micromachines, Volume 12, Issue 9
%D 2021
%V 12
%N 9
%I MDPI AG
%F Escobar-2021-Integrated
%X The rapid detection and quantification of infectious pathogens is an essential component to the control of potentially lethal outbreaks among human populations worldwide. Several of these highly infectious pathogens, such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been cemented in human history as causing epidemics or pandemics due to their lethality and contagiousness. SARS-CoV-2 is an example of these highly infectious pathogens that have recently become one of the leading causes of globally reported deaths, creating one of the worst economic downturns and health crises in the last century. As a result, the necessity for highly accurate and increasingly rapid on-site diagnostic platforms for highly infectious pathogens, such as SARS-CoV-2, has grown dramatically over the last two years. Current conventional non-microfluidic diagnostic techniques have limitations in their effectiveness as on-site devices due to their large turnaround times, operational costs and the need for laboratory equipment. In this review, we first present criteria, both novel and previously determined, as a foundation for the development of effective and viable on-site microfluidic diagnostic platforms for several notable pathogens, including SARS-CoV-2. This list of criteria includes standards that were set out by the WHO, as well as our own “seven pillars” for effective microfluidic integration. We then evaluate the use of microfluidic integration to improve upon currently, and previously, existing platforms for the detection of infectious pathogens. Finally, we discuss a stage-wise means to translate our findings into a fundamental framework towards the development of more effective on-site SARS-CoV-2 microfluidic-integrated platforms that may facilitate future pandemic diagnostic and research endeavors. Through microfluidic integration, many limitations in currently existing infectious pathogen diagnostic platforms can be eliminated or improved upon.
%R 10.3390/mi12091079
%U https://gwf-uwaterloo.github.io/gwf-publications/G21-118001
%U https://doi.org/10.3390/mi12091079
%P 1079
Markdown (Informal)
[Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms](https://gwf-uwaterloo.github.io/gwf-publications/G21-118001) (Escobar et al., GWF 2021)
ACL
- Andres Escobar, Phyllis Chiu, Jianxi Qu, Yushan Zhang, Chang‐Qing Xu, Andres Escobar, Phyllis Chiu, Jianxi Qu, Yushan Zhang, and Chang‐Qing Xu. 2021. Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms. Micromachines, Volume 12, Issue 9, 12(9):1079.
